EP3922263A4 - Ad7 vector vaccine for preventing sars-cov-2 infection - Google Patents
Ad7 vector vaccine for preventing sars-cov-2 infection Download PDFInfo
- Publication number
- EP3922263A4 EP3922263A4 EP21763207.4A EP21763207A EP3922263A4 EP 3922263 A4 EP3922263 A4 EP 3922263A4 EP 21763207 A EP21763207 A EP 21763207A EP 3922263 A4 EP3922263 A4 EP 3922263A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- cov
- infection
- vector vaccine
- preventing sars
- sars
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10371—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010182122 | 2020-03-16 | ||
CN202010293658 | 2020-04-15 | ||
CN202011031062.0A CN112206318B (en) | 2020-03-16 | 2020-09-27 | Ad7 vector vaccine for preventing SARS-CoV-2 infection |
PCT/CN2021/074837 WO2021184987A1 (en) | 2020-03-16 | 2021-02-02 | Ad7 vector vaccine for preventing sars-cov-2 infection |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3922263A1 EP3922263A1 (en) | 2021-12-15 |
EP3922263A4 true EP3922263A4 (en) | 2022-06-29 |
Family
ID=77768327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21763207.4A Withdrawn EP3922263A4 (en) | 2020-03-16 | 2021-02-02 | Ad7 vector vaccine for preventing sars-cov-2 infection |
Country Status (3)
Country | Link |
---|---|
US (1) | US20230127808A1 (en) |
EP (1) | EP3922263A4 (en) |
WO (1) | WO2021184987A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110616199A (en) * | 2019-06-26 | 2019-12-27 | 广州恩宝生物医药科技有限公司 | Replication-defective recombinant human 7-type adenovirus and preparation method and application thereof |
WO2021000968A2 (en) * | 2020-02-23 | 2021-01-07 | 广州恩宝生物医药科技有限公司 | Adenovirus carrier vaccine used for preventing sars-cov-2 infection |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1276777C (en) * | 2003-05-21 | 2006-09-27 | 中山大学肿瘤防治中心 | SARS vaccine of adenovirus carrier and preparation method, application of coronavirus S gene |
WO2004110483A1 (en) * | 2003-05-31 | 2004-12-23 | Yiyou Chen | Method and composition of a novel vaccine design for the prevention and treatment of sars |
CN110974950B (en) * | 2020-03-05 | 2020-08-07 | 广州恩宝生物医药科技有限公司 | Adenovirus vector vaccine for preventing SARS-CoV-2 infection |
CN110951756B (en) * | 2020-02-23 | 2020-08-04 | 广州恩宝生物医药科技有限公司 | Nucleic acid sequence for expressing SARS-CoV-2 virus antigen peptide and its application |
CN112206318B (en) * | 2020-03-16 | 2021-08-03 | 广州恩宝生物医药科技有限公司 | Ad7 vector vaccine for preventing SARS-CoV-2 infection |
-
2021
- 2021-02-02 WO PCT/CN2021/074837 patent/WO2021184987A1/en unknown
- 2021-02-02 EP EP21763207.4A patent/EP3922263A4/en not_active Withdrawn
- 2021-02-02 US US17/598,659 patent/US20230127808A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110616199A (en) * | 2019-06-26 | 2019-12-27 | 广州恩宝生物医药科技有限公司 | Replication-defective recombinant human 7-type adenovirus and preparation method and application thereof |
WO2021000968A2 (en) * | 2020-02-23 | 2021-01-07 | 广州恩宝生物医药科技有限公司 | Adenovirus carrier vaccine used for preventing sars-cov-2 infection |
EP3805392A2 (en) * | 2020-02-23 | 2021-04-14 | Guangzhou N Biomed Ltd. | Nucleic acid sequence expressing sars-cov-2 virus antigen peptide and use thereof |
Non-Patent Citations (4)
Title |
---|
AHMED SYED FARAZ ET AL: "Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies", VIRUSES, vol. 12, no. 3, 25 February 2020 (2020-02-25), CH, pages 1 - 15, XP055823903, ISSN: 1999-4915, DOI: 10.3390/v12030254 * |
DATABASE EMBL [online] EBI; 15 January 2020 (2020-01-15), ZHANG Y.-Z. ET AL: "Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1, complete genome.", XP055796635, Database accession no. MN908947 * |
NAN X ET AL: "Development of an Ad7 cosmid system and generation of an Ad7[Delta]E1[Delta]E3HIVMN env/rev recombinant virus", GENE THERAPY, NATURE PUBLISHING GROUP, LONDON, GB, vol. 10, no. 4, 1 February 2003 (2003-02-01), pages 326 - 336, XP037772808, ISSN: 0969-7128, [retrieved on 20030210], DOI: 10.1038/SJ.GT.3301903 * |
See also references of WO2021184987A1 * |
Also Published As
Publication number | Publication date |
---|---|
US20230127808A1 (en) | 2023-04-27 |
WO2021184987A1 (en) | 2021-09-23 |
EP3922263A1 (en) | 2021-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2592769B (en) | CpG-Adjuvanted SARS-CoV-2 virus vaccine | |
EP4126037A4 (en) | Attenuated poxvirus vector based vaccine for protection against covid-19 | |
EP3804751A4 (en) | Adenovirus carrier vaccine used for preventing sars-cov-2 infection | |
GB202002166D0 (en) | Vaccine | |
EP4103722A4 (en) | Rapid vaccine platform | |
GB202006662D0 (en) | Means for reducing virus self infection | |
EP4185323A4 (en) | Aav5-based vaccine against sars-cov-2 | |
EP3895730A4 (en) | Vaccine for preventing or treating congenital infection with cytomegalovirus | |
EP3960241A4 (en) | Therapeutic agent for flavivirus infection | |
EP3922263A4 (en) | Ad7 vector vaccine for preventing sars-cov-2 infection | |
AU2022257033A1 (en) | Pseudorabies virus vaccine | |
EP3912638A4 (en) | Ad35 vector vaccine for preventing sars-cov-2 infection | |
EP4021925A4 (en) | Methods of increasing vaccine efficacy | |
GB202016954D0 (en) | Vaccine | |
AU2021903076A0 (en) | SARS-CoV2 Vaccine | |
EP4065595A4 (en) | Immunogenic protein against gonococcal infection | |
AU2019904450A0 (en) | Immunogenic protein against gonococcal infection | |
EP4125764A4 (en) | Device for limiting infection | |
EP4114848A4 (en) | Pd-1-based vaccines against coronavirus infection | |
AU2021902566A0 (en) | Vaccine compositions | |
AU2020901004A0 (en) | Device for Limiting Infection | |
AU2020903062A0 (en) | Treatment for viral infection | |
EP4284385A4 (en) | Methods for preventing viral infection | |
GB202318238D0 (en) | Vaccine | |
GB202301244D0 (en) | Vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210910 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20220530 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 11/00 20060101ALI20220523BHEP Ipc: A61P 31/14 20060101ALI20220523BHEP Ipc: A61K 39/215 20060101AFI20220523BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20230103 |